30 closest matches · ranked by relevance
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
Myelodysplastic Syndrome
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days — 30.8; 11.9 Percentage of Participants — p=0.0005
Myelodysplastic Syndrome
Primary: Response Signature in Transfusion Dependent MDS Patients — 24; 1; 17; 6 Participants
Anemia
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC) — 2.5; 26.9…
Anemia · Myelodysplastic Syndromes
Primary: Proportion of Patients Free of Transfusion at 4 Months — 0.459; 0.714 Proportion of patients
Leukemia · Myelodysplastic Syndromes
Primary: PHASE I: Maximum Tolerated Dose of Azacitidine — 75 mg/m2 subcutaneously for 5 days
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence — 59 participants
Leukemia
Primary: Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA) — 0; 0; 0; 0 participants
de Novo Myelodysplastic Syndromes · Previously Treated Myelodysplastic Syndromes · Secondary Myelodysplastic Syndromes
Primary: Frequency of Hematologic Responses, as Defined by International Working Group (IWG) Criteria — 14; 8; 1; 7 Participants
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days) — 3; 20; 23 Participants — p=<0.001
Acute Myelogenous Leukemia · Myelodysplastic Syndrome · Leukemia
Primary: Number of Participants With Complete Remission — 0; 0; 0; 2 participants
Leukemia · Myeloproliferative Diseases
Primary: Number of Participants With Complete Response (CR) — 19 Participants
Myelodysplastic Syndrome
Primary: Number of Participants With Response — 2; 2; 4; 6 participants
Adult Myelodysplastic Syndrome · Anemia · Chronic Myelomonocytic Leukemia
Primary: Number of Patients Demonstrating Overall Hematologic Improvement (HI) — 6; 5; 7 Participants
Leukemia · Leukemia, Myeloid · Monocytic Leukemia
Primary: Clinical Response: Hematological Improvement - Erythroid (HI-E) — 0; 0 participants
Myelodysplastic Syndrome · MDS
Primary: Number of Participants With Erythroid Response — 5 participants
Myelodysplastic Syndromes
Primary: Percentage of Participants With Clinical Response as Measured by the International Working Group (IWG) Criteria for Hematological Improvement — 50.00; 71.43; 100.00…
MDS · Myelodysplastic Syndromes · Thrombocytopenia
Primary: Occurrence of a Clinically Significant Thrombocytopenic Event — 11; 8; 10; 11 Participants
Myelodysplastic Syndrome · Aplastic Anemia
Primary: Overall Response — 8; 8; 4 participants
Myelodysplastic Syndromes
Primary: Response to Treatment - Hematologic Improvement or Complete Response — 21 Participants
Myelodysplastic Syndromes (MDS)
Primary: Overall Survival — 55; 58 Participants
Myelodysplastic Syndrome · Acute Myeloid Leukemia
Primary: Phase I: Recommended Phase II Dose — 20 mg/day
Myelodysplastic Syndromes
Primary: Proportion of Participants Achieving Erythroid Response at Week 12 as Assessed by International Working Group (IWG) 2006 Response Criteria — 60 Participants
Anemia, Aplastic · Anemia, Hypoplastic · Thrombocytopenia
Primary: The Portion of Drug Responders as Defined by Hematologic Improvements — 17 Participants
Myelodysplastic Syndromes
Primary: Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24 — 37.91; 13.16 Percent of Participants…